FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:1354-1361 November 17, 1994 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

The ability of tricyclic antidepressant drugs to inhibit the prejunctional reuptake of norepinephrine and serotonin may be responsible for their antidepressant effect. The ability of these drugs to block muscarinergic, H₁-histaminergic, and ₁-adrenergic receptors may explain their side effects, such as dryness of the mouth, sedation, and hypotension. The development of drugs that inhibit the reuptake of norepinephrine and serotonin but do not have receptor-blocking effects started in the early 1970s.

Fluoxetine (Prozac), a selective inhibitor of serotonin reuptake, is now the most widely prescribed antidepressant drug in the United States and is also commonly prescribed in other countries. . . . [Full Text of this Article]

Pharmacodynamics

Pharmacokinetics

Clinical Indications

Depression

Dose-Effect Studies

Comparative Studies

Methodologic Problems in Studies of Depression

Tolerability and Adverse Effects

Drug Interactions

Summary

Source Information

From the Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Winslowparken 19, DK-5000 Odense C, Denmark, where reprint requests should be addressed to Dr. Gram.

References

Related Letters:

Fluoxetine
Blomgren S. L., Tollefson G. D., Castiella A., Lopez P., Arenas J. I., Gram L. F.
Extract | Full Text  
N Engl J Med 1995; 332:960-961, Apr 6, 1995. Correspondence

This article has been cited by other articles:

• Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B., Li, C. (2007). Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 35: 1292-1300 [Abstract] [Full Text]  
• Traboulsie, A., Chemin, J., Kupfer, E., Nargeot, J., Lory, P. (2006). T-Type Calcium Channels Are Inhibited by Fluoxetine and Its Metabolite Norfluoxetine. Mol. Pharmacol. 69: 1963-1968 [Abstract] [Full Text]  
• Cohen, J. S (2004). Antidepressants: An Avoidable and Solvable Controversy. The Annals of Pharmacotherapy 38: 1743-1746 [Full Text]  
• Kim, J., Riggs, K. W., Rurak, D. W. (2004). STEREOSELECTIVE PHARMACOKINETICS OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS IN PREGNANT SHEEP. Drug Metab. Dispos. 32: 212-221 [Abstract] [Full Text]  
• Camilleri, M (2002). Serotonergic modulation of visceral sensation: lower gut. Gut 51: i81-86 [Abstract] [Full Text]  
• Bray, G. A., Greenway, F. L. (1999). Current and Potential Drugs for Treatment of Obesity. Endocr. Rev. 20: 805-875 [Abstract] [Full Text]  
• Goodnick, P. J., Goldstein, B. J. (1998). Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life. J Psychopharmacol 12: S21-S54 [Abstract]  
• Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G.W., Kulin, N., Koren, G. (1997). Neurodevelopment of Children Exposed in Utero to Antidepressant Drugs. NEJM 336: 258-262 [Abstract] [Full Text]  
• Dam, M., Tonin, P., De Boni, A., Pizzolato, G., Casson, S., Ermani, M., Freo, U., Piron, L., Battistin, L. (1996). Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy. Stroke 27: 1211-1214 [Abstract] [Full Text]  
• Barnett, M. L. (1995). The Assessment of New Biotechnologies: Would the World be Different if Napoleon had Received Recombinant Growth Hormone?. JDR 74: 1820-1821  
• Blomgren, S. L., Tollefson, G. D., Castiella, A., Lopez, P., Arenas, J. I., Gram, L. F. (1995). Fluoxetine. NEJM 332: 960-961 [Full Text]